120017
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.6 Breast Cancer (Dove Med Press)
- 4.3 Clin Epidemiol
- 2.6 Cancer Manag Res
- 3.2 Infect Drug Resist
- 4.1 Clin Interv Aging
- 6.1 Drug Des Dev Ther
- 4.1 Int J Chronic Obstr
- 8.7 Int J Nanomed
- 2.5 Int J Women's Health
- 3.2 Neuropsych Dis Treat
- 2.4 OncoTargets Ther
- 2.6 Patient Prefer Adher
- 2.6 Ther Clin Risk Manag
- 3.1 J Pain Res
- 3.5 Diabet Metab Synd Ob
- 4.5 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 2.4 Pharmgenomics Pers Med
- 2.6 Risk Manag Healthc Policy
- 4.6 J Inflamm Res
- 2.3 Int J Gen Med
- 3.9 J Hepatocell Carcinoma
- 3.3 J Asthma Allergy
- 2.5 Clin Cosmet Investig Dermatol
- 3.0 J Multidiscip Healthc
已发表论文
HIV 感染者合并马尔尼菲篮状菌和隐球菌感染的临床特征、管理和结局：一项回顾性病例系列
Authors Zou J, Qin X, Lu Y, Jiang Z, Zheng Y, Nai J, Wu J, Chen M
Received 6 August 2025
Accepted for publication 29 January 2026
Published 8 February 2026 Volume 2026:19 558689
DOI https://doi.org/10.2147/IDR.S558689
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Professor Chi H. Lee
Jun Zou,1,* Xiaoying Qin,2,* Yangni Lu,3,* Zhiwen Jiang,4,5 Yanqing Zheng,1 Jianye Nai,1 Jianlin Wu,6 Maowei Chen6
1Department of Infectious Disease, The Fourth People’s Hospital of Nanning, Nanning, People’s Republic of China; 2Guangxi Medical University, Nanning, People’s Republic of China; 3Department of Gastroenterology, The People’s Hospital of Laibin City, Laibin, People’s Republic of China; 4Department of Dermatology and Venereology, The First Affiliated Hospital of Guangxi Medical University, Nanning, People’s Republic of China; 5Guangxi Key Laboratory of Mycosis Prevention and Treatment, Nanning, Guangxi, People’s Republic of China; 6Department of Infectious Diseases, Wuming Hospital Affiliated with Guangxi Medical University, Nanning, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Maowei Chen, Email chenmaowei2008@163.com Jianlin Wu, Email wjl4954@163.com
Background: Talaromycosis and Cryptococcosis are life-threatening opportunistic infections that occur in severely immunocompromised individuals. However, data on the clinical characteristics, management, and outcomes of patients with concurrent Talaromyces marneffei and Cryptococcus infections are limited.
Methods: We performed a retrospective review of the electronic medical records of patients living with human immunodeficiency virus (PLHIV) who were diagnosed with concurrent Talaromyces marneffei and Cryptococcus infection between January 2013 and December 2023. Risk factors for poor outcomes were determined through univariate and multivariate analyses.
Results: Most patients were male (72.3%) with advanced immunosuppression (median CD4 count: 15 cells/μL). Constitutional symptoms (91.5%) were most common, followed by gastrointestinal (55.3%) and respiratory symptoms (53.2%). Blood cryptococcal antigen testing was the most frequent method for detecting Cryptococcus in co-infected patients. The overall mortality rate was 29.8%. Cerebrospinal fluid (CSF) lactate dehydrogenase (LDH) > 21.15 U/L was identified as an independent predictor of mortality (OR = 13.1, 95% CI: 1.27– 135.76, p = 0.031).
Conclusion: Co-infection with T. marneffei and Cryptococcus in HIV patients is associated with nonspecific clinical presentations and high mortality. Elevated CSF LDH levels, particularly CSF LDH levels > 21.15 U/L, are a significant risk factor for death. Early cryptococcal antigen screening and prompt antifungal therapy are crucial for improving outcomes in this population.
Keywords: Talaromyces marneffei, Cryptococcus, coinfection, fungal infection, HIV
1Department of Infectious Disease, The Fourth People’s Hospital of Nanning, Nanning, People’s Republic of China; 2Guangxi Medical University, Nanning, People’s Republic of China; 3Department of Gastroenterology, The People’s Hospital of Laibin City, Laibin, People’s Republic of China; 4Department of Dermatology and Venereology, The First Affiliated Hospital of Guangxi Medical University, Nanning, People’s Republic of China; 5Guangxi Key Laboratory of Mycosis Prevention and Treatment, Nanning, Guangxi, People’s Republic of China; 6Department of Infectious Diseases, Wuming Hospital Affiliated with Guangxi Medical University, Nanning, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Maowei Chen, Email chenmaowei2008@163.com Jianlin Wu, Email wjl4954@163.com
Background: Talaromycosis and Cryptococcosis are life-threatening opportunistic infections that occur in severely immunocompromised individuals. However, data on the clinical characteristics, management, and outcomes of patients with concurrent Talaromyces marneffei and Cryptococcus infections are limited.
Methods: We performed a retrospective review of the electronic medical records of patients living with human immunodeficiency virus (PLHIV) who were diagnosed with concurrent Talaromyces marneffei and Cryptococcus infection between January 2013 and December 2023. Risk factors for poor outcomes were determined through univariate and multivariate analyses.
Results: Most patients were male (72.3%) with advanced immunosuppression (median CD4 count: 15 cells/μL). Constitutional symptoms (91.5%) were most common, followed by gastrointestinal (55.3%) and respiratory symptoms (53.2%). Blood cryptococcal antigen testing was the most frequent method for detecting Cryptococcus in co-infected patients. The overall mortality rate was 29.8%. Cerebrospinal fluid (CSF) lactate dehydrogenase (LDH) > 21.15 U/L was identified as an independent predictor of mortality (OR = 13.1, 95% CI: 1.27– 135.76, p = 0.031).
Conclusion: Co-infection with T. marneffei and Cryptococcus in HIV patients is associated with nonspecific clinical presentations and high mortality. Elevated CSF LDH levels, particularly CSF LDH levels > 21.15 U/L, are a significant risk factor for death. Early cryptococcal antigen screening and prompt antifungal therapy are crucial for improving outcomes in this population.
Keywords: Talaromyces marneffei, Cryptococcus, coinfection, fungal infection, HIV